ASX listed biotech Company PharmAust has made significant progress in reformulating its promising anti-cancer drug Monepantel to improve its taste and deliver increased dosages of the substance in each pill. Monepantel has already shown pleasing results in initial clinical trials as a cancer treatment in humans and canines, with further tests of the drug planned for 2018.
21/09/2017 - 05:59
PharmAust hits milestone in anti-cancer drug reformulation
By Matt Birney
21/09/2017 - 05:59
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX